Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
10.65
+0.24 (2.31%)
At close: Nov 19, 2026, 4:00 PM EST
10.66
+0.01 (0.09%)
After-hours: Nov 19, 2026, 4:10 PM EST
Eloxx Pharmaceuticals Employees
Eloxx Pharmaceuticals had 10 employees as of December 31, 2025. The number of employees decreased by 8 or 44.44% compared to the previous year. That makes Eloxx Pharmaceuticals the 40,254th largest employer in the world and 6,014th in the United States.
Employees
10
Change
-8
Growth
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,584,300
Market Cap
42.99M
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10 | -8 | -44.44% |
| Dec 31, 2022 | 18 | -10 | -35.71% |
| Dec 31, 2021 | 28 | 3 | 12.00% |
| Dec 31, 2020 | 25 | -4 | -13.79% |
| Dec 31, 2019 | 29 | 0 | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Clene | 79 |
| Xilio Therapeutics | 76 |
| Verrica Pharmaceuticals | 76 |
| Spero Therapeutics | 25 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
| RenovoRx | 17 |
ELOX News
- 1 day ago - Eloxx Pharmaceuticals’ exaluren shows efficacy in Alport syndrome trial - TheFly
- 1 day ago - Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation - PRNewsWire
- 3 days ago - Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update - PRNewsWire
- 3 days ago - Eloxx Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 3 days ago - Eloxx Pharmaceuticals Earnings release: Q3 2026 - Filings
- 10 days ago - Eloxx Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 10 days ago - Eloxx Pharmaceuticals Slides: Corporate presentation - Filings
- 17 days ago - Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference - PRNewsWire